Founded in 2014, Singlera Genomics focuses on the R&D and clinical application of NGS (next generation sequencing) and molecular diagnostics. Providing solutions for the prevention, occurrence, and development of high-risk tumors, especially the development and application of non-invasive DNA methylation-based early cancer screening and diagnosis.
Singlera Genomics (Chinese: 鹍远生物) completed a Series B+ round of financing worth CNY 300 million (USD 44.85 million), led by Forestone Capital (Chinese: 沣石资本), followed by China Stock (Chinese: 银河源汇), Guojing Innovation Investment (Chinese: 国经投资), Junci Investment (Chinese: 隽赐投资), Unifortune (Chinese: 乾道投资), Bestd (Chinese: 佰仕德), Brilliance Fairview Fund (Chinese: 华晨美景基金) and Sansure Biotech (Chinese: 圣湘生物) followed as a strategic investor.
The fund is mainly used to expand the early cancer screening product pipeline and promote its registration, production, commercialization, and international market development.
Their product pipeline has covered pan-cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, esophageal cancer, pancreatic cancer, and thyroid cancer. It is reported that PanSeer®, a methylated circulating tumor DNA (ctDNA) pan-cancer screening technology independently developed by Singlera, is the first to conduct a large cohort study universally.
Early cancer screening can effectively improve the patients’ survival rate and has high clinical and social value. Singlera Genomics’s competitors include Burning Rock (Chinese: 燃石医学), Exact Sciences (Chinese: 精密科学), BerryGenomics (Chinese: 贝瑞基因), and Nuohui Health (Chinese: 诺惠健康).